Minnesota House Bill HF3609

Minnesota 2025-2026 Regular Session

• Introduced: 2/23/26
• Refer: 2/23/26

Caption

Disallowance of drug manufacturers from restricting delivery of 340B prescription drugs continued, enforcement provided, and expiration date removed.

Impact

The implications of HF3609 on state laws are considerable. By preventing drug manufacturers from imposing restrictions on the delivery of 340B drugs, the bill aims to strengthen access to affordable medications for specifically designated healthcare providers. This could have a positive impact on the healthcare system by ensuring that disadvantaged populations continue to receive necessary prescriptions at reduced costs. The provision making violations an unfair or deceptive trade practice reinforces the regulatory framework enabling the Attorney General to enforce the bill's provisions effectively.

Summary

House File 3609 (HF3609) is a bill designed to continue the prohibition against drug manufacturers restricting the delivery of 340B prescription drugs. The bill is significant in the realm of healthcare regulation, as it seeks to ensure that eligible entities can access discount drugs under the 340B program without interference from manufacturers. This bill modifies existing Minnesota Statutes to not only fortify this prohibition but also eliminates an expiration date tied to such restrictions, thereby solidifying the permanence of these protections.

Contention

While HF3609 has garnered support due to its focus on preserving access to essential medications, it may face opposition based on concerns regarding the enforcement mechanisms it establishes. Some stakeholders might argue that maintaining open delivery channels for 340B drugs could impose additional burdens on drug manufacturers and potentially complicate their distribution logistics. Additionally, there may be debates surrounding the broader implications of labeling violations as deceptive practices, which some might view as an overreach or excessive regulation of the pharmaceutical industry.